Holcomb John Bradley 4

What Happened

• John Bradley Holcomb, a director of MiNK Therapeutics (INKT), was granted restricted stock units (RSUs) as board/committee compensation. He received 1,239 RSUs on 2026-03-02 at an implied value of $10.90 each ($13,505) and 1,091 RSUs on 2026-06-01 at $12.38 each ($13,507), for a combined total of 2,330 RSUs worth about $27,012. These were awards (code A) — not open-market purchases or sales.

Key Details

• Transaction dates & values:
  • 2026-03-02: 1,239 RSUs @ $10.90 each = $13,505 (grant)
  • 2026-06-01: 1,091 RSUs @ $12.38 each = $13,507 (grant)
• Shares owned after the transactions: Not specified in the provided filing excerpt.
• Footnotes:
  • F1: RSUs represent a contingent right to receive one share per RSU; these RSUs were issued in lieu of cash retainers and will vest one month after each grant date.
  • F2: The RSUs for Q1 2026 board/committee compensation (the 3/2/2026 grant) were not filed timely due to an administrative error; the Form 4 was filed 2026-06-02.
• Filing timeliness: The filing notes a late/reporting issue for the Q1 RSUs (administrative error). Late filings can delay public transparency but do not change the nature of the award.

Context

• These are compensation awards, not purchases or sales. RSU grants are a routine form of board compensation and do not by themselves indicate an insider buying or selling shares for market exposure.
• RSUs vest one month after each grant date (per the filing); once vested they convert to shares (and may be subject to tax withholding or sale depending on the director’s actions, which are not shown here).